TrialBritish journal of cancer2015

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial.

N Beije et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.